2seventy bio rises on sale of blood disorder treatment to Novo Nordisk

2Seventy Bio

26/06/2024 23:41

** Shares of 2seventy bio  TSVT.O  rise 7.2% to $3.86 in
extended trading  
    ** Co says Novo Nordisk  NOVOb.CO  has acquired its gene
therapy candidate to treat hemophilia A and rights to one of its
gene editing technology for up to $40 million 
    ** Hemophilia A is a hereditary bleeding disorder caused by
a lack of blood clotting factor VIII  
    ** TSVT says it will focus exclusively on the
commercialization and continued development of Bristol Myers
Squibb-partnered cancer therapy, Abecma  
    ** Up to last close, TSVT shares down ~16% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))